A bdominal colectomy and ileal pouch-anal anastomosis (IPAA) has become the standard operative approach for patients with ulcerative colitis (UC) requiring colectomy for dysplasia, cancer, or medically refractory disease. Despite excellent functional results and high patient satisfaction, 1,2 pouchitis remains a significant clinical problem. For example, objective measurement tools have shown that pouchitis patients have a poorer quality of life compared with patients who have not developed pouchitis. 3, 4 The mucosal inflammation observed in UC usually starts in the rectum and over time extends into more proximal colonic segments, usually in a continuous fashion. UC does not typically involve other areas of the intestinal tract, although mucosal inflammation proximal to the ileocecal valve is occasionally seen and is termed backwash ileitis (BWI). 5 The association of BWI with patients undergoing IPAA and pouchitis remains controversial. Although some studies have found higher rates of pouchitis in BWIϩ patients, 6 -8 other papers have suggested that BWIϩ patients have outcomes comparable with BWIϪ patients. 9 -11 These conflicting results arise from a number of factors, including study design, small patient numbers, suboptimal patient follow-up, and referral center bias typical of these studies.
In this prospective study, we investigated the outcome of IPAA in a longitudinally-followed cohort of consecutive UC patients with BWI who were operated on by a single surgeon. In addition, we examined whether any clinical or serologic factors could predict outcome in patients with BWI.
METHODS

Study Population
As part of a prospective study to examine clinical, serologic, and genetic markers with clinical phenotypes, patients with UC, inflammatory bowel disease unclassified (IBDU), or indeterminate colitis (IC) who required colectomy for medically unresponsive disease or dysplasia over an eleven-year period ending June 2008 were studied. All research-related activities were approved by the Cedars-Sinai Medical Center Institutional Review Board (IRB #3358). Complete mucosectomy was performed in all patients by one surgeon (PRF). In addition, all patients had a temporary diverting ileostomy constructed at the time of pouch creation.
Assessment of Clinical Characteristics
Detailed clinical profiles assessing demographic information and characteristics of the disease and its treatment were prospectively generated by one investigator (PRF) using chart reviews and patient interviews. Although we practice in a tertiary referral center, all patients were closely followed by one investigator (PRF). Patients were seen for follow-up examinations every 3 months for the first year after stoma closure, and yearly afterwards. Only patients followed for minimum of 3 months were included in this analysis.
Assessed demographic information included patient age at surgery, sex, and length of follow-up after surgery. Examined disease characteristics included disease duration, perianal disease, transmural disease, extraintestinal manifestations (EIM), family history of inflammatory bowel disease (IBD), and the diagnosis of UC, IBDU, or IC. Extraintestinal manifestations noted before colectomy included primary sclerosing cholangitis (PSC), skin lesions (pyoderma gangrenosum, erythema nodosum), bone/ joint disease (arthritis, ankylosing spondylitis, sacroiliitis), and eye disease (uveitis, episcleritis) considered by the investigators and the patients' physicians to be manifestations of IBD. The diagnosis of PSC was based on clinical findings and confirmed in all cases using liver biopsy. Disease duration referred to the time interval between IBD diagnosis and the date of colectomy. Tabulated treatment characteristics included the nature of medical therapy before colectomy (steroids alone vs the use of other immunomodulators) and indications for surgery (medically refractory disease vs dysplasia/cancer).
Diagnosis of Backwash Ileitis
Backwash ileitis was defined as neutrophilic inflammation in the lamina propria and/or epithelium in the distal 3 cm of the terminal ileum. Features suggestive of chronic ileitis (such as pyloric metaplasia or villous architectural distortion) were not considered within the pathologic spectrum of BWI, and these cases were excluded. The macroscopic or histological evidence of acute inflammation restricted to the distal 3 cm of the extreme terminal ileum was not thought to be related to Crohn's disease (CD). Patients with ulcerations isolated to the ileocecal valve were not considered to have BWI.
Diagnosis of Ulcerative Colitis, Inflammatory Bowel Disease Unclassified, and Indeterminate Colitis
Clinical, endoscopic and pathologic criteria were reviewed in all patients to determine if they had UC, IBDU, or IC according to the Montreal Classification. 12 Clinically, UC patients had no perianal disease, and endoscopic features included continuous macroscopic disease extending varying distances from the dentate line. Radiologic evaluation revealed the distinct absence of either a colonic stricture or small-bowel disease 3 cm proximal to the ileocecal valve. Histologic patterns of continuous microscopic inflammation and the absence of noncaseating granulomas were mandatory to rule out CD. Additionally, these features were also identified after review of intraoperative findings and pathologic evaluation of the resected specimen. Patients were classified as having IBDU when they had preoperative clinical, endoscopic, or pathologic criteria of UC with some features suggestive of but not diagnostic of CD. Preoperative features included discontinuous inflammation possibly related to medical therapy, history of an anal fistula or ulcer that was inactive at the time of surgery, noncaseating granulomas thought to be related to crypt rupture, or small bowel inflammation not involving the terminal ileum. Patients were classified as having IC when they had postoperative clinical, endoscopic, or pathologic criteria of UC with some features suggestive of but not diagnostic of CD. Postoperative pathologic features of IC included gross or microscopic transmural colonic inflammation or discontinuous histopathologic involvement of the colon possibly related to medical therapy, history of an anal fistula or ulcer that was inactive at the time of surgery, noncaseating granulomas thought to be related to crypt rupture, or small bowel inflammation not involving the terminal ileum. According to these criteria, all patients were classified before surgery as having either UC or IBDU. Immediately after histopathologic evaluation of the resected specimen, all patients were then reclassified as having either UC or IC. Patients with granulomatous inflammation on histopathologic examination not thought to be related to a ruptured crypt were deemed to have CD and were excluded from analysis.
Diagnosis of Pouchitis and Crohn's Disease
Pouchitis was defined as a clinical syndrome characterized by the onset of increased stool frequency, often with bloody diarrhea, pelvic discomfort, urgency, malaise, and fever. The diagnosis of pouchitis was confirmed in all cases by endoscopy with afferent ileal limb intubation. Endoscopic findings in cases of pouchitis included diffuse mucosal inflammation, typically involving the entire pouch, characterized by exudate, ulceration, erythema, and sparing of the afferent ileal segment. Histopathologic evaluation of the pouch was not routinely performed. Acute pouchitis (AP) was defined as flares treated favorably with antibiotics, occurring at least 4 months apart, during which time the patient was completely asymptomatic and had returned to his or her usual bowel pattern. Chronic pouchitis (CP) required continuous antibiotic treatment for symptom relief, and also included those patients who did not respond to antibiotic treatment. Stool studies were obtained when conventional antibiotic therapy was unsuccessful, or in patients with CP. However, pouchoscopy with biopsies was performed in all CP patients looking for granulomatous inflammation or cytomegalovirus inclusion bodies. 13 De novo CD after IPAA was diagnosed either when mucosal inflammation (5 or more ulcers) involved the small bowel mucosa proximal to the ileal pouch 14 anytime after surgery, or when a pouch fistula or other perianal complication developed more than 3 months after ileostomy closure. For patients with persistent symptoms, studies were done to exclude mechanical complications of surgery such as an anal stricture or partial small bowel obstruction. Patients using nonsteroidal anti-inflammatory drugs were also excluded from analysis. 15 Time to diagnosis of pouchitis or de novo CD was defined as the time period from ileostomy closure.
Serologic Analysis
Serum was drawn immediately before colectomy, coded, and stored for future analysis. All sera were analyzed in a blinded fashion by Prometheus Laboratories (San Diego, CA) or performed at Cedars-Sinai Medical Center.
Stored serum was analyzed for expression of IBDassociated antibodies, including anti-Saccharomyces cerevisiae (ASCA), anti-outer membrane of porin C (anti-OmpC), anti-CBir1, anti-I2, and perinuclear antineutrophil cytoplasmic antibody (pANCA) in a blinded fashion by enzyme-linked immunosorbent assay (ELISA), as previously described. 16 -18 All assays for anti-I2 were performed at Cedars-Sinai Medical Center. Antibody levels were determined and results expressed as ELISA units (EU/ml), which relate to Cedars-Sinai Laboratory (OmpC-IgA, anti-I2, and anti-CBir1) or Prometheus Laboratory (pANCA, ASCA-IgA, and IgG) standards that were derived from a pool of patient sera with well-characterized disease found to have reactivity to these antigens. Qualitative positivity to any antibody was defined as cut-off values greater than 2 SD above mean control titers for each assay. All assays were performed blindly without knowledge of patient clinical characteristics. Similarly, clinical course after IPAA was assessed without knowledge of the patient's serologic profile.
Our group has previously reported that patients having sera with high pANCA levels (Ͼ 100 ELISA units per milliliter) are predisposed to the development of chronic pouchitis but not acute pouchitis. 19 These data suggest that high-level pANCA expression may identify a subset of patients with UC who may have a distinct type of mucosal inflammation representing an exquisite sensitivity to the presence of bacterial antigens. This observation stimulated our analysis of patients not only on pANCA positivity/ negativity but also on the magnitude of antibody expression, namely antibody level. pANCAϩ patients were thus stratified into 2 groups based on antibody level. High-level pANCAϩ patients had levels equal to or above 100 ELISA units per milliliter. Low-level pANCAϩ patients had levels below 100 ELISA units per milliliter
Statistical Analysis
All data were entered into a standardized database computer program (Microsoft Excel, Seattle, WA). For continuous covariates, medians were compared using Wilcoxon nonparametric tests. Categorical variables were compared using 2 or the Fisher exact probability test (if expected cell counts were less than 5). Univariate time-to-event analysis using Cox proportional hazards modeling was separately performed for each outcome variable (acute pouchitis, chronic pouchitis, or de novo Crohn's disease outcomes relative to those with no pouch complications) based on the presence or absence of BWI (R, The R Project for Statistical Computing). In addition, univariate time-to-event analyses were performed on each potential predictor variable for each of the 3 outcomes, with the intent to include all variables with log-rank P Ͻ .15 into a multivariate model. All hypothesis testing was two-sided, with a P value of less than 0.05 considered statistically significant (JMP 8.0, The SAS Institute, Carey, NC).
RESULTS
Patient Demographics and Clinical Characteristics
Patient demographic and clinical characteristics of the 334 study patients are shown in Table 1 . The majority of the patients were male. Of the 281 patients with medically unresponsive disease, 47 (17%) were steroid-dependent and 234 (83%) were refractory to other immunomodulatory therapy, including thiopurines (n ϭ 205), cyclosporin (n ϭ 96) and/or infliximab (n ϭ 51). Seventy-three patients (22%) had EIMs associated with their disease, including arthritis (n ϭ 50), PSC (n ϭ 12), skin disease (n ϭ 10), and uveitis (n ϭ 1). Although the majority of patients had surgery for medically refractory disease, IPAA was performed in 38 patients for dysplasia and 15 patients for an established carcinoma. Before surgery, 237 patients (71%) had UC and the remaining 97 patients (29%) had IBDU. The diagnosis of IBDU was based on discontinuous inflammation (n ϭ 65), anal disease (n ϭ 14), involvement of the small bowel proximal to the terminal ileum (n ϭ 9), and crypt-associated granulomas (n ϭ 9). After histologic evaluation of the resected specimen, there were a total of 236 UC patients and 98 IC patients. The diagnosis of IC was based on transmural inflammation on the colectomy specimen (n ϭ 41), discontinuous inflammation (n ϭ 21), crypt-associated granulomas (n ϭ 14), involvement of the small bowel proximal to the terminal ileum (n ϭ 11), and anal disease (n ϭ 11).
Clinical Characteristics and Seromarker Expression in Backwash Ileitis
Backwash ileitis was identified in 39 patients (12%). There were a number of significant differences in clinical characteristics between patient groups with or without BWI (Table 2). All patients with BWI had pancolitis. The incidence of pancolitis was significantly higher in the BWIϩ patient group than in the BWIϪ patient group (P ϭ .0001). Although there was no significant difference in the overall incidence of EIM, PSC was significantly more common in BWIϩ patients than in BWIϪ patients. A majority of BWIϩ patients had atypical features of UC both before surgery (IBDU) and after surgery (IC). The diagnosis of IBDU in BWIϩ patients was based on discontinuous inflammation (n ϭ 10), involvement of the small bowel above the terminal ileum (n ϭ 5), anal disease (n ϭ 4), and crypt-associated granulomas (n ϭ 1). The diagnosis of IC in BWIϩ patients was based on involvement of the small bowel above the terminal ileum (n ϭ 8), transmural inflammation on the colectomy specimen (n ϭ 5), discontinuous inflammation (n ϭ 4), anal disease (n ϭ 4), and crypt-associated granulomas (n ϭ 2). The incidence of both IBDU and IC was much higher in BWIϩ patients than in BWIϪ patients. As complete serology data was not available in 7 study patients, serologic analysis was performed on the remaining 327 study patients (BWIϩ, 38; BWIϪ, 289). Serum pANCA, anti-I2, anti-OmpC, anti-CBir1 and ASCA were detected in 220 patients (67%), 88 patients (27%), 68 patients (21%), 61 patients (19%), and 42 patients (13%), respectively ( Table 3 ). Among the 42 ASCAϩ patients were 32 who were ASCA IgAϩ, 18 who were ASCA IgGϩ, and 8 who expressed both forms of ASCA. The frequency of high-level pANCA expression was significantly higher in BWIϩ patients than in BWIϪ patients. No other significant differences in either frequency of serologic marker positivity or median antibody level were noted between the BWIϩ and BWIϪ patient groups.
Pouchitis Development
After a median follow-up time after ileostomy closure of 26 (range, 3-492) months, 90 patients developed pouchitis, representing an overall incidence of 27%. Median time to diagnosis of pouchitis was 9 (range, 3-116) months. Acute pouchitis was seen in 53 patients (16%). Median time to the diagnosis of AP was 10 (range, 3-166) months. The median number of acute pouchitis episodes per patient was 2 (range, 1-5). Chronic pouchitis developed in 37 patients (11%). Twenty-nine patients with CP were maintained on long-term antibiotic therapy. Four patients required a diverting ileostomy to control symptoms, 2 required immunomodulator therapy, and 2 were controlled using probiotic therapy alone. The median time to CP development was 6 (range, 3-53) months. There was no significant difference in median time to pouchitis diagnosis between patients with acute pouchitis and patients with chronic pouchitis.
Forty-two patients (13%) developed de novo CD of the pouch after IPAA. Median time to de novo CD diagnosis was 8 (range, 1-53) months. One patient developed de novo CD of the pouch and proximal limb of the ileostomy one month after IPAA creation. All of the remaining patients developed de novo CD more than 3 months after ileostomy closure. De novo CD was diagnosed on the basis of afferent ileal limb disease (n ϭ 32), pouch fistulizing disease (n ϭ 5), and new perianal disease (n ϭ 5). Twentysix patients were maintained on immunosuppressive therapy, 11 required a diverting ileostomy to control persistent symptoms after failing aggressive immunosuppression, and 5 were controlled with antibiotics alone.
Relationship Between Backwash Ileitis and Outcome After IPAA
The association between the BWIϩ and BWIϪ patient groups and outcome after IPAA is shown in Table 4 . There was no significant difference in the overall rate of development of AP, CP, or de novo CD using Cox proportional hazards modeling (log-rank P values, 0.63, 0.05, 0.96, respectively). Although there was a higher incidence of CP in BWIϩ patients (21%) than in BWIϪ patients (10%), this trend did not reach statistical significance. Since PSC, a well-described risk factor for CP, 11, 20 was more common in the BWIϩ patient group, we evaluated the association of BWI in patients who did not have PSC (n ϭ 322). Within this subgroup, CP was observed in 5 of the 33 BWIϩ patients (15%) vs 27 of the 289 BWIϪ patients (9%; P ϭ .35). Median time to diagnosis of acute pouchitis, chronic pouchitis, and de novo CD were similar between BWIϩ and BWIϪ patient groups (data not shown).
Factors Associated With Outcome in Patients With Backwash Ileitis
Associations of clinical characteristics and individual serologic responses to microbial antigens and outcome after IPAA in the BWIϩ patient group are shown in Tables 5  and 6 . None of the clinical variables examined was associated with either a favorable or adverse outcome in the BWIϩ patient group. From a serological point of view, both anti-I2 and pANCA expression were not associated with any adverse outcome after surgery. Anti-OmpC was significantly associated with the development of de novo CD after IPAA. Although anti-CBir1 was also associated with de novo CD after IPAA, this trend was of borderline significance. ASCA-IgA expression was associated with the onset of chronic pouchitis. These trends were not observed in BWIϩ patients who did not have PSC. Furthermore, we were unable to demonstrate any significant association when combining individual serologic markers and outcome after IPAA (data not shown).
DISCUSSION
As long as symptoms are controlled by medical measures and no dysplasia or cancer develops, UC patients with BWI are managed with medical therapy in a similar fashion to UC patients without BWI. However, when colectomy is indicated, the distinction between BWIϩ and BWIϪ may become important. Surgical outcomes after IPAA in BWI patients are controversial, with some studies reporting adverse effects of BWIϩ compared with BWIϪ, and other studies showing no difference ( Table 7) . Many of these studies are retrospective in design, include small patient numbers, have suboptimal patient follow-up, and are plagued with referral center bias. These discrepant data may also be partially explained by problems in clinical definitions of both BWI and pouchitis. The overall incidence of BWI varies significantly across studies (6%-22%), corresponding with inconsistent clinical and pathologic criteria used to reach a diagnosis of BWI. Some studies have considered BWI to include not only patients with acute inflammation (ie, the presence of neutrophils), but also patients who have chronic inflammation (ie, lymphocytes) or morphologic features of regenerative changes without inflammation. We defined patients to have BWI only when there was acute inflammation in the extreme terminal ileum, corresponding with other expert opinions on this issue. 20 Some authors define pouchitis on clinical grounds alone, whereas others require endoscopic confirmation. Although we do not believe that histologic assessment, as defined in the Pouchitis Disease Activity Index, 21 is necessary for the diagnosis of pouchitis, it is clear that symptoms alone are not sufficient to accurately diagnose this condition. 22 Our study revealed a number of clinical phenotypes associated with BWI. The incidence of pancolitis was much higher in BWIϩ patients than in BWIϪ patients, corroborating the data of others. 7, 10 In fact, all of the BWI patients in our study had pancolitis. These data suggest that the presence of terminal ileal inflammation in a left-sided colitis patient should seriously raise the possibility of CD and not UC. The incidence of PSC was significantly higher in BWIϩ patients than in BWIϪ patients, also confirming the results of prior studies. 23, 24 Since bile acids are absorbed in the terminal ileum, it is interesting to speculate that the defects in bile acid metabolism noted in PSC patients 25 might account for the relationship between BWI and PSC.
Our study has several limitations. As a referral center, our patient population may have more aggressive or advanced disease at the time of surgery. However, one might conceive that this would actually bias results toward worse postoperative outcomes among those with ileal inflammation suggestive of backwash ileitis. As a second limitation, although the median duration to developing pouch inflammation was 9 months, some patients in the cohort were followed for fewer than 9 months. Thus, the possibility exists that these patients could develop pouch complications if they were followed up for a longer duration. Finally, our results are reported from the database of a single surgeon, and thus may not be readily generalizable.
A unique aspect of the current study was the evaluation of subclinical markers in BWI patients. There was no significant difference in serologic marker expression between BWIϩ and BWIϪ patients, except that BWIϩ patients did have a significantly higher incidence (29%) of high-level pANCA expression than BWIϪ patients (9%).
Although the mechanism responsible for the relationship between high levels of the antimicrobial antibody pANCA 26 and BWI is not well understood, it supports the concept that luminal factors such as bacteria or their excreted products play an integral role in BWI development. Our group has previously shown that ASCA positivity is a prominent feature of patients with well-characterized small bowel CD. 17, 18 The low incidence of both ASCA-IgA (5%) and ASCA-IgG (3%) observed in BWIϩ patients strongly suggests that the presence of BWI itself should dissuade clinicians from thinking these patients all have CD and not UC. Serologic differences noted between BWIϩ and BWIϪ patients in the current study require validation from other centers.
From the surgical point of view, we observed no significant differences between patients with BWI and patients without BWI in the development of acute pouchitis, chronic pouchitis, or de novo CD after IPAA. We also attempted to identify subgroups of BWI patients, based on clinical or subclinical features, with either a favorable or adverse outcome after IPAA. None of the clinical variables were significantly associated with outcome in BWIϩ patients. Although anti-OmpC was significantly associated with the development of de novo CD, and ASCA-IgA expression was associated with the onset of chronic pouchitis after IPAA, none of these trends were observed in BWIϩ patients who did not have PSC. These data suggest that in the absence of PSC, the clinical outcome of IPAA in patients with BWI cannot be predicted. Colorectal surgeons should feel comfortable in performing an IPAA in patients with BWI, especially in the absence of PSC.
In summary, this prospective study has shown that BWIϩ patients appear to have the same overall incidence of acute pouchitis, chronic pouchitis, and de novo CD after IPAA as do BWIϪ patients. Preoperative counseling of these patients should clearly include a discussion of these findings. 
